{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:57:14Z","timestamp":1783702634863,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014931","name":"Arrowhead Pharmaceuticals Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014931","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jhep.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T22:46:55Z","timestamp":1521586015000},"page":"378-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients"],"prefix":"10.1016","volume":"69","author":[{"given":"Alice M.","family":"Turner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Stolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Lickliter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn R.","family":"Christianson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Given","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Burdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Stoller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery H.","family":"Teckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.03.012_b0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.molmed.2013.11.006","article-title":"Alpha-1-antitrypsin deficiency: clinical variability, assessment, and treatment","volume":"20","author":"Stockley","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jhep.2018.03.012_b0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1513\/AnnalsATS.201410-452OC","article-title":"The Swedish alpha1-antitrypsin screening study: health status and lung and liver function at age 34","volume":"12","author":"Tanash","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jhep.2018.03.012_b0015","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1016\/S0168-8278(11)60892-1","article-title":"ALT abnormalities in adults with alpha-1 antitrypsin deficiency","volume":"54","author":"Clark","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.03.012_b0020","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1164\/rccm.201204-0739OC","article-title":"Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease","volume":"187","author":"Dawwas","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhep.2018.03.012_b0025","first-page":"279A","article-title":"Liver fibrosis is present in one-third of adults with alpha-1 antitrypsin deficiency without overt liver disease","volume":"62","author":"Clark","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.03.012_b0030","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/00042737-199610000-00010","article-title":"Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma?","volume":"8","author":"Elzouki","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.03.012_b0035","first-page":"B51","article-title":"Alpha-1-antitrypsin deficiency and liver in adults","volume":"45","author":"Triger","year":"1976","journal-title":"Q J Med"},{"key":"10.1016\/j.jhep.2018.03.012_b0040","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3109\/00365520903296669","article-title":"The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency","volume":"44","author":"Bernspang","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.03.012_b0045","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM198603203141202","article-title":"Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency","volume":"314","author":"Eriksson","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.03.012_b0050","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2011.12.028","article-title":"Diagnosis and management of patients with alpha1-antitrypsin (A1AT) deficiency","volume":"10","author":"Nelson","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.03.012_b0055","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1164\/rccm.168.7.818","article-title":"Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency","volume":"168","author":"American Thoracic Society\/European Respiratory Society statement","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhep.2018.03.012_b0060","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/lt.24434","article-title":"Is severe progressive liver disease caused by alpha-1-antitrypsin deficiency more common in children or adults?","volume":"22","author":"Chu","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2018.03.012_b0065","series-title":"Organ donation and transplantation activity report 2014\/2015","author":"National Health Service Blood and Transplant","year":"2016"},{"key":"10.1016\/j.jhep.2018.03.012_b0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/17474124.2014.943187","article-title":"Alpha-1 antitrypsin and liver disease: mechanisms of injury and novel interventions","volume":"9","author":"Teckman","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.03.012_b0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1172\/JCI67968","article-title":"Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice","volume":"124","author":"Guo","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2018.03.012_b0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/15412555.2013.765839","article-title":"Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy","volume":"10","author":"Teckman","year":"2013","journal-title":"COPD"},{"key":"10.1016\/j.jhep.2018.03.012_b0085","first-page":"68A","article-title":"RNA interference therapeutic ARC-AAT prevents production of Z-alpha1 antitrypsin polymers and reverses liver disease phenotype in PiZ mouse model","volume":"64","author":"Wooddell","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.03.012_b0090","unstructured":"Haslett P. A randomized, single-blind, placebo-controlled, phase 1\/2 study of ALN-AAT, an investigational RNAi therapeutic for the treatment of alpha-1 antitrypsin deficiency associated liver disease. 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS); Montreal, Canada: Oligonucleotide Therapeutics Society; September 28, 2016."},{"key":"10.1016\/j.jhep.2018.03.012_b0095","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2018.03.012_b0100","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jhep.2011.09.024","article-title":"Clinical evidence for the regression of liver fibrosis","volume":"56","author":"Ellis","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.03.012_b0105","first-page":"A1569","article-title":"Improving survival among ZZ patients in the Alphanet Program","volume":"193","author":"Choate","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhep.2018.03.012_b0110","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","article-title":"Performance of transient elastography for the staging of liver fibrosis: a meta-analysis","volume":"134","author":"Friedrich-Rust","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.03.012_b0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/apt.13691","article-title":"Magnetic resonance elastography identifies fibrosis in adults with alpha-1 antitrypsin deficiency liver disease: a prospective study","volume":"44","author":"Kim","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.03.012_b0120","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/MEG.0b013e328347daaf","article-title":"Performance of enhanced liver fibrosis plasma markers in asymptomatic individuals with ZZ alpha1-antitrypsin deficiency","volume":"23","author":"Janciauskiene","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.03.012_b0125","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.rmed.2008.01.009","article-title":"Alpha-1 antitrypsin null mutations and severity of emphysema","volume":"102","author":"Fregonese","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.jhep.2018.03.012_b0130","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2147\/COPD.S130440","article-title":"Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review","volume":"12","author":"Edgar","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818301764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818301764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:33:45Z","timestamp":1759174425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818301764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0168827818301764"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.03.012","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732895908.793544234","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}